BC Week In Review | Jan 5, 2018
Clinical News

Mereo reports Phase II data for COPD candidate acumapimod

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase II trial in 282 patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) showing that low- and high-dose acumapimod (BCT-197) plus standard of...
BC Week In Review | May 19, 2017
Clinical News

Mereo completes enrollment in Phase II of acumapimod for COPD exacerbations

Mereo BioPharma Group plc (LSE:MPH) completed enrollment of 282 patients in the international Phase II AETHER trial evaluating acumapimod (BCT-197) to treat acute exacerbations of chronic obstructive pulmonary disease (COPD). The company expects top-line data...
BC Week In Review | Aug 3, 2015
Company News

Novartis, Mereo BioPharma deal

Start-up Mereo acquired three Phase II compounds from Novartis in exchange for an undisclosed equity stake. Novartis is eligible for milestone payments and royalties. BPS-804 is a human mAb for the Orphan bone disease osteogenesis...
BioCentury | Aug 3, 2015

From Phase4 to Mereo

The leadership team behind Phase4 Ventures is branching out from its traditional venture roots to launch newco Mereo BioPharma Group Ltd. , which aims to provide an alternative for pharmas looking to advance mid-stage pipelines in...
BC Extra | Jul 30, 2015
Top Story

Mereo raises $119M, acquires three Novartis programs<span class="*Red-type+bold">

Mereo BioPharma Group Ltd. (London, U.K.) debuted on Wednesday with $119 million (L76.7 million) and three clinical-stage programs acquired from Novartis AG (NYSE:NVS; SIX:NOVN). Woodford Investment Management and Invesco Perpetual invested in Mereo; Novartis also...
Items per page:
1 - 5 of 5